Abstracts tagged "Remission and spondylarthritis"

Abstract Number: 315 • 2018 ACR/ARHP Annual Meeting
Assessing the Value of Whole Body Magnetic Resonance Imaging As to Clinical Examination to Predict Remission and Relapse in Early Peripheral Spondyloarthritis
Thomas Renson¹, Ann-Sophie De Craemer¹, Philippe Carron¹, Simon Krabbe², Lennart Jans³, Manouk de Hooge⁴, Peggy Jacques¹, Mikkel Østergaard⁵, Dirk Elewaut¹ and Filip van Den Bosch⁶, ¹Department of Rheumatology, Ghent University Hospital, Ghent, 9000, Belgium, ²Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, ³Department of Radiology, Ghent University Hospital, Ghent, Belgium, ⁴Ghent University Hospital, Ghent, Belgium, ⁵Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁶Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose: Evaluation of disease activity and treatment response in peripheral spondyloarthritis (pSpA) is currently based upon clinical findings, laboratory tests and ultrasound examination. Whole-body magnetic…
Abstract Number: 2573 • 2018 ACR/ARHP Annual Meeting
The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Targeting Disease Remission in Axial Spondyloarthritis: A Systematic Literature Review
Ana Rita Machado^1,2, Santiago Rodrigues Manica^3,4, Joana Leite Silva⁵, Fernando Pimentel-Santos^3,4, José Tavares Costa⁵ and Elsa Vieira-Sousa^1,2, ¹Unidade de Investigação em Reumatologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, Lisboa, Portugal, ²Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal, Lisboa, Portugal, ³Rheumatology, Hospital de Egas Moniz - Centro Hospitalar Lisboa Ocidental, EPE, Lisbon, Portugal, ⁴CEDOC, NOVA Medical School, Lisbon, Portugal, ⁵Rheumatology, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal
Background/Purpose: The treat-to-target concept is currently recommended in Axial Spondyloarthritis (axSpA) and remission is the main objective of treatment. Although consensual definitions of remission are…
Abstract Number: 2005 • 2016 ACR/ARHP Annual Meeting
Exploring the Window of Opportunity for Drug-Free Clinical Remission in Patients with Active, Very Early Peripheral Spondyloarthritis
Philippe Carron¹, Gaëlle Varkas², Heleen Cypers², Liesbet Van Praet¹, Dirk Elewaut² and Filip van Den Bosch¹, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, VIB, Ghent University and Ghent University Hospital, Ghent, Belgium
Background/Purpose: To evaluate drug-free sustained clinical remission and clinical relapse after induction therapy with golimumab in patients with active peripheral Spondyloarthritis (pSpA) in a very…
Abstract Number: 650 • 2015 ACR/ARHP Annual Meeting
ASDAS-Based Remission Was Less Frequent Than Basdai-Based Remission, and Both Were Related to CRP and Smoking in Early Axial Spondyloarthritis
Daniel Wendling¹, Xavier Guillot², Laure Gossec³, Clément Prati⁴, Alain Saraux⁵ and Maxime Dougados⁶, ¹Université de Franche-Comté, Besançon, France, ²Service de Rhumatologie, CHRU J Minjoz, Besançon, France, ³Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Cochin University Hospital, Paris, France
Background/Purpose: Remission is the final goal for treat to target strategy in axial spondyloarthritis (axSpA). No clear definition is currently recognized, but ASDAS-CRP inactive state…
Abstract Number: 2836 • 2015 ACR/ARHP Annual Meeting
Early Clinical Response Is a Better Predictor of Long-Term Remission Than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis
Filip van Den Bosch¹, Philip J. Mease², Joachim Sieper³, Dominique Baeten⁴, Nupun A. Varothai⁵, Aileen L. Pangan⁵ and In-Ho Song⁵, ¹Ghent University Hospital, Ghent, Belgium, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: ABILITY-2 has demonstrated the efficacy of adalimumab (ADA) vs. placebo (PBO) over 12 weeks (wk) in patients (pt) with peripheral spondyloarthritis (pSpA)1 and sustained…
Abstract Number: 2862 • 2015 ACR/ARHP Annual Meeting
Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa¹, Emilio Martín-Mola¹, Daniel Seoane-Mato³ and Juan D. Cañete⁴, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: Anti-TNF therapy is successful for achieving low disease activity (LDA) or clinical remission in patients with axial spondyloarhritis (axSpA). Nevertheless, this therapy has not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].